Cardiff Oncology Shares Collapse After Phase 2 Onvansertib Update
Cardiff Oncology's stock fell almost 30% in premarket trading Tuesday after the company released Phase 2 data for onvansertib combined with standard first-line therapy in RAS-mutated metastatic colorectal cancer. While the 30mg arm produced a notably higher confirmed objective response rate than standard of care and was well-tolerated, the market r…